OZEM240719C15000
- 11.74
- 0.000.00%
Roundhill GLP-1 & Weight Loss ETF Newsroom
Insauce (22nd) [earnings schedule]
*The above calendar is subject to change depending on the circumstances of the company. --------------------------------------- July 22 (Mon) <6200> Insource --------------------------------------- July 23 (Tue) <4722> Future <6594> Nidec Corporation Sponsored ADR <6999> KOA <7211> Mitsubishi Motors
Here Are Big Pharma's Leading Blockbuster Makers
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
US stocks closed with all three major indices falling, with the S&P Nasdaq index seeing its largest weekly decline in three months. Technology stocks weakened, with Tesla down more than 4%, Nvidia down more than 2%, and CrowdStrike down more than 11%.
Investors accelerated their escape from technology stocks, with stocks and bonds in Europe and the United States being hit hard for two days. This week, the S&P 500 and Nasdaq fell by about 2% and 3.7%, respectively. The Nasdaq stopped its six-week continuous rise, while the Dow and small-cap indices rose by 0.7% and 1.7%, respectively. Chip stocks fell more than 3% on Friday and nearly 9% for the week. Nvidia also fell more than 8.7% for the past three months, making it the worst performer. The "seven sisters of technology" all fell for the week, and cybersecurity leader Crowdstrike, which triggered a global technology outage, fell 11% on Friday, the worst in nearly two years. The VIX panic index rose more than 32% for the week.
Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 12 unusual trades.Delving into the details, we found 66%
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
Eli Lilly Weight Loss Drug Approved in China
Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. stock indices were down, with the Dow Jones Industrial Average dropping nearly 1.3% to 40,665.03, the S&P 500 falling almost 0.8% to 5,544.59, and the Nasdaq decreasing 0.7% to 17,871.22.
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Top 10 S&P 500 Stocks Down More Than 5% From Last Week
Eli Lilly, Novo Extend Muti-day Decline in Rare Selloff
Shares of weight loss drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) extended a multi-day decline on Thursday, losing billions of dollars in market capitalization for two of the world’s biggest companies.
What's Going On With Eli Lilly And Company Shares Thursday?
Eli Lilly and Company (NYSE:LLY) stock is moving lower on Thursday on possible continued weakness after recent weight loss data from Roche.What To Know: On Wednesday, Roche announced positive Phase
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic
Least Shorted S&P 500 Stocks in June
Cosmos Pharmaceuticals, 7&I-HD, etc. (additional) Rating
Target stock price change code | Stock name | Securities company | Previous | After change | ------ | ------------- | ------------- | --------- | --------- | <2802> | Ajinomoto | GS | 6800 yen | 7000 yen | <2914> | JT | GS | 4400 yen | 4600 yen | <3349> | Cosmos Pharmaceutical | Mizuho
Big Pharma Rally After J&J Earnings
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
The famed Danish drug maker Novo Nordisk A/S (NYSE:NVO) expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company's popular weight-loss drug, Wegovy, in the basic insurance coverage.
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.What happened?
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 8.54% on an annualized basis producing an average annual return of 19.47%. Currently, Novo Nordisk has a market